Browse studies

Find your next paid study

1 recruiting study matching your filters

MT2025-14: A Phase 1a/1b Study of GTB-5550, a Camelid Nanobody TriSpecific Killer Engager (camB7-H3 TriKE®), in Select Advanced Solid Tumors That Failed Prior Therapy

This is a first-in-human Phase 1a/1b trial of a B7-H3-targeted natural killer (NK) cell engager, referred to as a TriSpecific Killer Engager (TriKE), for the t…

Tri-specific Killer EngagerSolid TumorAdvanced Solid Tumor

Masonic Cancer Center, University of MinnesotaNCT07541573